Corporate Presentation

Obesity Petrelintide Six, once-weekly, low doses of petrelintide resulted in average weight loss above 5% Part 1 of the Phase 1b MAD trial of petrelintide ZEAL& ZEALAND PHARMA Change in body weight (%) 5 -10- Placebo (n=6) LO 5 -0.4% Petrelintide 0.6 mg (n=7) -5.3% T T Petrelintide 1.2 mg (n=7) -5.1% Dosing T 0 1 2 3 4 5 6 7 8 9 10 11 12 13 0 1 2 3 4 5 6 7 8 9 10 11 12 13 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Weeks after first dose Source: Figure adapted from Olsen et al. Poster presented at ObesityWeek, October 14-17, 2023, Dallas, TX. MAD=multiple ascending dose. 16

View entire presentation